Mixed reviews for Amgen's KRAS drug after lung cancer data r...

Eagerly awaited trial data from Amgen’s latest KRAS-targeting cancer drug AMG 510 emerged over the weekend – and the results have received broadly positive reviews.

Who will be the biggest pharma players in orphan drugs?

New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Roche coming out in the lead.

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9...

Boehringer jumps on KRAS cancer drug bandwagon with MD Ander...

Boehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, striking a multi-year oncology research deal with the University of Tex

Three years after approval, court blocks US launch of Enbrel...

Sandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel (etanercept) inflammatory diseases drug in the US, three years after appr

Cancer update buoys Amgen despite Q2 sales fall